Synaptics to Participate at Upcoming Investor Conferences Thursday, February 26, 2026 and Tuesday, March 3, 2026 SAN JOSE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced its participation in upcoming investor conferences. Ken Rizvi, Chief Financial Officer, will participate in Susquehanna’s Fifteenth Annual Technology Conference on Thursday, February 26, 2026Rahul Patel, President and Chief Executive Officer, and Ken Rizvi, Chief Financial Officer, will participate in Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 3, ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the “Options”) as inducem...
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the comp...
Synaptics Reports Second Quarter Fiscal 2026 Results Core IoT product sales increased 53% year-over-year Q2'26 Financial Results Revenue of $302.5 million, up 13% year-over-yearFiscal second quarter Core IoT product sales grew by 53% year-over-yearGAAP gross margin of 43.5%Non-GAAP gross margin of 53.6%GAAP loss per share of $0.38Non-GAAP diluted earnings per share of $1.21 SAN JOSE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Synaptics Incorporated (Nasdaq: ) today reported financial results for its second quarter of fiscal 2026 ended December 27, 2025. Net revenue for the second qua...
Lesaka’s Q2 FY2026 Results: Lesaka achieves mid-point of its profitability guidance and reaffirms its FY2026 full year guidance JOHANNESBURG, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the second quarter of fiscal 2026 (“Q2 2026”). Q2 2026 performance1:All growth rates are year-on-year between Q2 FY2026 and Q2 FY2025. Group LevelUSD(In thousands, except per share data) ZAR(In thousands, except per share data) Q2 FY26 Q2 FY25 Q2 FY26 Q2 FY25 YoY%Revenue178,734 176,216 3,058,191 3,155,758 (3%)Net Revenue(2)93,403 77,0...
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts ...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company’s common stock...
Standard BioTools Completes Sale of SomaLogic to Illumina Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announ...
We are taking 3Q25 results and the most recent cNPS data and laying out our latest thinking and forecasts ahead of 4Q results. We expect 4Q results and attendant 2026 guidance to contain material information value for investors and we wanted to share our latest forecasts, data, and trends as a starting point as we navigate this impactful season.
Synaptics to Report Second Quarter Fiscal 2026 Results on February 5, 2026 SAN JOSE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced that it will report financial results for the second quarter of fiscal 2026 on Thursday, February 5, 2026, after the market closes. The Company will host a corresponding conference call for analysts and investors at 2:00 p.m. PT (5:00 p.m. ET), to discuss the results. To participate on the live call, analysts and investors should pre-register at . Registrants will receive dial-in information and a unique passcod...
Earlier this month DISH filed an antitrust complaint against DIS in the latest chapter of a long running dispute over DIS’s efforts to create new sports bundles and DISH’s efforts to create new options for how its customers access programming over its platform. In this note we explore the implications of the battle, how it might affect the flexibility of content and distribution in seeking to adjust to thrive in the media world to come, and what it could tell us about the direction of media and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.